<?xml version='1.0' encoding='utf-8'?>
<document id="28260951"><sentence text="The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects."><entity charOffset="14-22" id="DDI-PubMed.28260951.s1.e0" text="apixaban" /><entity charOffset="50-57" id="DDI-PubMed.28260951.s1.e1" text="digoxin" /><entity charOffset="62-70" id="DDI-PubMed.28260951.s1.e2" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.28260951.s1.e0" e2="DDI-PubMed.28260951.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s1.e0" e2="DDI-PubMed.28260951.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s1.e0" e2="DDI-PubMed.28260951.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s1.e1" e2="DDI-PubMed.28260951.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s1.e1" e2="DDI-PubMed.28260951.s1.e2" /></sentence><sentence text="Apixaban is often coadministered with treatments for cardiovascular comorbidities, which may lead to unintended drug-drug interactions (DDIs)"><entity charOffset="0-8" id="DDI-PubMed.28260951.s2.e0" text="Apixaban" /></sentence><sentence text=" The effects of apixaban on pharmacokinetics (PK) of multidose Lanoxin® (digoxin) and single-dose Tenormin® (atenolol) and the effects of single-dose atenolol on apixaban PK in healthy subjects were investigated in two Phase 1 studies"><entity charOffset="16-24" id="DDI-PubMed.28260951.s3.e0" text="apixaban" /><entity charOffset="73-80" id="DDI-PubMed.28260951.s3.e1" text="digoxin" /><entity charOffset="98-106" id="DDI-PubMed.28260951.s3.e2" text="Tenormin" /><entity charOffset="109-117" id="DDI-PubMed.28260951.s3.e3" text="atenolol" /><entity charOffset="150-158" id="DDI-PubMed.28260951.s3.e4" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e0" e2="DDI-PubMed.28260951.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e0" e2="DDI-PubMed.28260951.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e0" e2="DDI-PubMed.28260951.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e0" e2="DDI-PubMed.28260951.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e0" e2="DDI-PubMed.28260951.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e1" e2="DDI-PubMed.28260951.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e1" e2="DDI-PubMed.28260951.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e1" e2="DDI-PubMed.28260951.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e1" e2="DDI-PubMed.28260951.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e2" e2="DDI-PubMed.28260951.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e2" e2="DDI-PubMed.28260951.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e2" e2="DDI-PubMed.28260951.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e3" e2="DDI-PubMed.28260951.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s3.e3" e2="DDI-PubMed.28260951.s3.e4" /></sentence><sentence text="" /><sentence text="The digoxin DDI study was an open-label, multidose, two-treatment, single-sequence study in which subjects received digoxin 0"><entity charOffset="116-123" id="DDI-PubMed.28260951.s5.e0" text="digoxin" /></sentence><sentence text="25 mg q6h on day 1, then once daily on days 2-10, followed by apixaban 20 mg and digoxin 0"><entity charOffset="62-70" id="DDI-PubMed.28260951.s6.e0" text="apixaban" /><entity charOffset="81-88" id="DDI-PubMed.28260951.s6.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.28260951.s6.e0" e2="DDI-PubMed.28260951.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s6.e0" e2="DDI-PubMed.28260951.s6.e1" /></sentence><sentence text="25 mg once daily on days 11-20" /><sentence text=" The atenolol DDI study was an open-label, single-dose, randomized, three-period, three-treatment, crossover study in which subjects received a single oral dose of apixaban 10 mg, atenolol 100 mg, or apixaban 10 mg plus atenolol 100 mg"><entity charOffset="164-172" id="DDI-PubMed.28260951.s8.e0" text="apixaban" /><entity charOffset="180-188" id="DDI-PubMed.28260951.s8.e1" text="atenolol" /><entity charOffset="200-208" id="DDI-PubMed.28260951.s8.e2" text="apixaban" /><entity charOffset="220-228" id="DDI-PubMed.28260951.s8.e3" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e0" e2="DDI-PubMed.28260951.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e0" e2="DDI-PubMed.28260951.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e0" e2="DDI-PubMed.28260951.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e0" e2="DDI-PubMed.28260951.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e1" e2="DDI-PubMed.28260951.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e1" e2="DDI-PubMed.28260951.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e1" e2="DDI-PubMed.28260951.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e2" e2="DDI-PubMed.28260951.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s8.e2" e2="DDI-PubMed.28260951.s8.e3" /></sentence><sentence text=" The 90% confidence intervals (CIs) for the ratios of geometric means of peak plasma concentration (Cmax) and area under the concentration-time curve (AUCtau), with and without apixaban were calculated"><entity charOffset="177-185" id="DDI-PubMed.28260951.s9.e0" text="apixaban" /></sentence><sentence text=" Absence of effect was concluded if the point estimates and 90% CI were within the equivalence interval of 80%-125% (digoxin) or 70%-143% (atenolol)"><entity charOffset="117-124" id="DDI-PubMed.28260951.s10.e0" text="digoxin" /><entity charOffset="139-147" id="DDI-PubMed.28260951.s10.e1" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.28260951.s10.e0" e2="DDI-PubMed.28260951.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s10.e0" e2="DDI-PubMed.28260951.s10.e1" /></sentence><sentence text=" A similar analysis was performed to assess the effect of atenolol on apixaban"><entity charOffset="58-66" id="DDI-PubMed.28260951.s11.e0" text="atenolol" /><entity charOffset="70-78" id="DDI-PubMed.28260951.s11.e1" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.28260951.s11.e0" e2="DDI-PubMed.28260951.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s11.e0" e2="DDI-PubMed.28260951.s11.e1" /></sentence><sentence text="" /><sentence text="Apixaban had no clinically relevant effect on the PK of either atenolol or digoxin: point estimates and 90% CI for both digoxin and atenolol Cmax and AUC were entirely within their respective no-effect intervals"><entity charOffset="0-8" id="DDI-PubMed.28260951.s13.e0" text="Apixaban" /><entity charOffset="63-71" id="DDI-PubMed.28260951.s13.e1" text="atenolol" /><entity charOffset="75-82" id="DDI-PubMed.28260951.s13.e2" text="digoxin" /><entity charOffset="108-110" id="DDI-PubMed.28260951.s13.e3" text="CI" /><entity charOffset="120-127" id="DDI-PubMed.28260951.s13.e4" text="digoxin" /><entity charOffset="132-140" id="DDI-PubMed.28260951.s13.e5" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e0" e2="DDI-PubMed.28260951.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e0" e2="DDI-PubMed.28260951.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e0" e2="DDI-PubMed.28260951.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e0" e2="DDI-PubMed.28260951.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e0" e2="DDI-PubMed.28260951.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e0" e2="DDI-PubMed.28260951.s13.e5" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e1" e2="DDI-PubMed.28260951.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e1" e2="DDI-PubMed.28260951.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e1" e2="DDI-PubMed.28260951.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e1" e2="DDI-PubMed.28260951.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e1" e2="DDI-PubMed.28260951.s13.e5" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e2" e2="DDI-PubMed.28260951.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e2" e2="DDI-PubMed.28260951.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e2" e2="DDI-PubMed.28260951.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e2" e2="DDI-PubMed.28260951.s13.e5" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e3" e2="DDI-PubMed.28260951.s13.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e3" e2="DDI-PubMed.28260951.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e3" e2="DDI-PubMed.28260951.s13.e5" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e4" e2="DDI-PubMed.28260951.s13.e4" /><pair ddi="false" e1="DDI-PubMed.28260951.s13.e4" e2="DDI-PubMed.28260951.s13.e5" /></sentence><sentence text=" Apixaban Cmax and AUCinf were slightly decreased (ie, 18% and 15% lower, respectively) following atenolol coadministration"><entity charOffset="1-9" id="DDI-PubMed.28260951.s14.e0" text="Apixaban" /><entity charOffset="98-106" id="DDI-PubMed.28260951.s14.e1" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.28260951.s14.e0" e2="DDI-PubMed.28260951.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s14.e0" e2="DDI-PubMed.28260951.s14.e1" /></sentence><sentence text=" No serious or major bleeding-related adverse events were reported during either study" /><sentence text="" /><sentence text="Apixaban had no effect on the PK of digoxin and there was no clinically relevant interaction between apixaban and atenolol"><entity charOffset="0-8" id="DDI-PubMed.28260951.s17.e0" text="Apixaban" /><entity charOffset="36-43" id="DDI-PubMed.28260951.s17.e1" text="digoxin" /><entity charOffset="101-109" id="DDI-PubMed.28260951.s17.e2" text="apixaban" /><entity charOffset="114-122" id="DDI-PubMed.28260951.s17.e3" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e0" e2="DDI-PubMed.28260951.s17.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e0" e2="DDI-PubMed.28260951.s17.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e0" e2="DDI-PubMed.28260951.s17.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e0" e2="DDI-PubMed.28260951.s17.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e1" e2="DDI-PubMed.28260951.s17.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e1" e2="DDI-PubMed.28260951.s17.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e1" e2="DDI-PubMed.28260951.s17.e3" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e2" e2="DDI-PubMed.28260951.s17.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s17.e2" e2="DDI-PubMed.28260951.s17.e3" /></sentence><sentence text=" Coadministration of digoxin or atenolol with apixaban in healthy subjects was generally well tolerated"><entity charOffset="21-28" id="DDI-PubMed.28260951.s18.e0" text="digoxin" /><entity charOffset="32-40" id="DDI-PubMed.28260951.s18.e1" text="atenolol" /><entity charOffset="46-54" id="DDI-PubMed.28260951.s18.e2" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.28260951.s18.e0" e2="DDI-PubMed.28260951.s18.e0" /><pair ddi="false" e1="DDI-PubMed.28260951.s18.e0" e2="DDI-PubMed.28260951.s18.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s18.e0" e2="DDI-PubMed.28260951.s18.e2" /><pair ddi="false" e1="DDI-PubMed.28260951.s18.e1" e2="DDI-PubMed.28260951.s18.e1" /><pair ddi="false" e1="DDI-PubMed.28260951.s18.e1" e2="DDI-PubMed.28260951.s18.e2" /></sentence><sentence text="" /></document>